PARTNERSHIPS
Partner with us
We are committed to creating best-in-class therapeutics for immunologic and inflammatory diseases. We welcome the opportunity to discuss collaborations with potential partners worldwide.
Partners
Inmagene and Hutchison China MediTech Limited (“HUTCHMED”) (NASDAQ/AIM: HCM) have formed a strategic partnership to develop IMG-007 and IMG-004 to treat a range of immunologic and inflammatory diseases. Led and funded by Inmagene, both products are in global clinical development.
To expedite the development of IMG-018, an in-house discovered asset via our proprietary QuadraTek® platform, Inmagene has partnered with Aditum Bio to establish Celexor Bio, a new biotech company. Celexor has licensed exclusive global rights to develop, manufacture, and commercialize IMG-018 from Inmagene.
To explore partnership opportunities, please contact our business development team by emailing bdpartner@inmagenebio.com.